Prothena to Report First Quarter 2022 Financial Results on May 5th
Prothena Corporation plc (NASDAQ:PRTA) will announce its first quarter 2022 financial results on May 5, 2022, after U.S. market close. The company specializes in investigational therapeutics targeting protein dysregulation, focusing on neurodegenerative and rare peripheral amyloid diseases. Prothena has a diverse pipeline aimed at treating conditions such as AL amyloidosis, ATTR amyloidosis, Alzheimer's, and Parkinson's diseases. Notably, there will be no conference call accompanying the results release.
- Prothena has a robust pipeline targeting critical neurodegenerative diseases.
- The company’s expertise in protein dysregulation supports potential advancements in therapeutics.
- No specific financial metrics were shared in the press release, which may limit investor insights.
DUBLIN, Ireland, April 28, 2022 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that it will report its first quarter 2022 financial results on Thursday, May 5, 2022 after the close of the U.S. financial markets.
Consistent with past practice, the Company will not be conducting a conference call in conjunction with this financial results release on May 5.
About Prothena
Prothena Corporation plc is a late-stage clinical biotechnology company with expertise in protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare peripheral amyloid diseases. Fueled by its deep scientific expertise built over decades of research, Prothena is advancing a pipeline of therapeutic candidates for a number of indications and novel targets for which its ability to integrate scientific insights around neurological dysfunction and the biology of misfolded proteins can be leveraged. Prothena’s pipeline includes both wholly-owned and partnered programs being developed for the potential treatment of diseases including AL amyloidosis, ATTR amyloidosis, Alzheimer’s disease, Parkinson’s disease and a number of other neurodegenerative diseases. For more information, please visit the Company’s website at www.prothena.com and follow the Company on Twitter @ProthenaCorp.
Contacts:
Media
Eric Endicott, Senior Vice President, Corporate Affairs
650-448-3670, eric.endicott@prothena.com
Investors
Jennifer Zibuda, Director, Investor Relations & Communications
650-837-8535, jennifer.zibuda@prothena.com
FAQ
When will Prothena report its Q1 2022 financial results?
Will there be a conference call for Prothena's Q1 2022 results?
What is Prothena's focus in its therapeutic pipeline?
What conditions are targeted by Prothena's pipeline?
